Based on the recommendations in the first NHS Genomics strategy (Accelerating Genomic Medicine in the NHS), NHS England has funded eight NHS Genomic Networks of Excellence. These networks are designed to provide a world-leading Genomic Medicine Service for patients in the NHS through partnerships with academia, the third sector and industry. These networks will develop evidence and models of adoption for genomic advances and technology applications that will be transformative for patients and ensure routes for commissioning decisions.
The Rare and Inherited Disease NHS Genomic Network of Excellence is led from the NHS South West, North West and North East and Yorkshire GMS Alliances. The aims of this Network include helping patients get faster diagnoses; reduce genomic health inequalities; develop new testing approaches, especially for those patients with a suspected rare disease that remain undiagnose
Based on the recommendations in the first NHS Genomics strategy (Accelerating Genomic Medicine in the NHS), NHS England has funded eight NHS Genomic Networks of Excellence. These networks are designed to provide a world-leading Genomic Medicine Service for patients in the NHS through partnerships with academia, the third sector and industry. These networks will develop evidence and models of adoption for genomic advances and technology applications that will be transformative for patients and ensure routes for commissioning decisions.
The Rare and Inherited Disease NHS Genomic Network of Excellence is led from the NHS South West, North West and North East and Yorkshire GMS Alliances. The aims of this Network include helping patients get faster diagnoses; reduce genomic health inequalities; develop new testing approaches, especially for those patients with a suspected rare disease that remain undiagnosed using current genomic testing; increase the efficiency of analysis; and increase capacity for rare condition clinical trials.
As part of the Rare and Inherited Disease NHS Genomic Network of Excellence, we in Manchester are leading a program of work to improve diagnosis of rare diseases by testing approaches for advanced data analysis and cutting edge technologies (e.g. DNA methylation testing, RNA sequencing and long read sequencing) and by developing new clinical pathways. We are also testing ways to enhance and accelerate adoption of clinical trials in rare diseases.
The Manchester team
Prof Siddharth Banka – Clinical and Academic lead
David Gokhale – Laboratory and Scientific lead
Christopher Campbell
Leigh Demain (PhD)
Christopher Kershaw (Healthcare Scientist)
Dr Deepak Babu
Dr Natalie Chaddock
Dr Adam Jackson